S2107 Adoptive immunotherapy
Also known as: cellular immunotherapy, CAR-T cell therapy
Adoptive immunotherapy. Infusion of patient-derived modified immune cells for cancer treatment.
In Plain Language
immune cell therapy; cancer cell therapy
Clinical Context
Infusion of genetically modified T-lymphocytes (CAR-T cells) or other immune cells targeting cancer cells. Requires careful monitoring for cytokine release syndrome.
RVU Information
CPT S2107 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
S-codes are used by private payers (not Medicare) for services without a standard CPT or HCPCS code. Coverage varies significantly between insurers. Verify payer acceptance before billing and document medical necessity thoroughly.
Specialties
Frequently Asked Questions
What is CPT code S2107?
CPT S2107 (Adoptive immunotherapy) is a S Codes code. Adoptive immunotherapy. Infusion of patient-derived modified immune cells for cancer treatment.
Is S2107 covered by insurance?
S2107 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Infusion of genetically modified T-lymphocytes (CAR-T cells) or other immune cells targeting cancer cells. Requires careful monitoring for cytokine release syndrome.
When is CPT S2107 used?
Infusion of genetically modified T-lymphocytes (CAR-T cells) or other immune cells targeting cancer cells. Requires careful monitoring for cytokine release syndrome.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.